Grifols SA Files Routine 6-K Update

Ticker: GIKLY · Form: 6-K · Filed: Apr 23, 2024 · CIK: 1438569

Grifols SA 6-K Filing Summary
FieldDetail
CompanyGrifols SA (GIKLY)
Form Type6-K
Filed DateApr 23, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, routine-update

TL;DR

Grifols SA filed a 6-K, no new info, just a routine update.

AI Summary

On April 23, 2024, Grifols, S.A. filed a Form 6-K to report other relevant information. The filing does not contain specific financial figures or new strategic announcements but serves as a routine update for the month of April 2024. Grifols, S.A. is a Spanish company operating in the pharmaceutical preparations sector.

Why It Matters

This filing is a standard disclosure for foreign private issuers, indicating ongoing compliance and reporting to the SEC. It does not contain new material information for investors at this time.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material information or significant financial updates.

Key Players & Entities

  • Grifols, S.A. (company) — Registrant
  • 0001104659-24-050357 (filing_id) — Accession Number
  • 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report other relevant information by Grifols, S.A. for the month of April 2024.

What is the filing date of this report?

This report was filed on April 23, 2024.

Is Grifols, S.A. required to file Form 20-F or Form 40-F annually?

Yes, Grifols, S.A. indicates it files annual reports under cover of Form 20-F.

What is the principal executive office address of Grifols, S.A.?

The principal executive office is located at Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, 08174 Barcelona, Spain.

What is the SIC code for Grifols, S.A.?

The Standard Industrial Classification code for Grifols, S.A. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 362 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-04-23 08:03:51

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. Grifols, S.A. By: /s/ David I. Bell Name: David I. Bell Title: Authorized Signatory Date: April 23, 2024 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.